Fig. 2. Autistic-like phenotypes induced by the striatal inhibition of MeCP2 or TSC1 were rescued by rebalancing glutamate or dopaminergic activity. (A) Experimental design of siRNA injection into the dorsal striatum and following behavioral tests. A diagram showing the siRNA injection sites in the dorsal striatum (AP, +1.0; ML, ±1.5; DV, −3.6 mm). (B, C) Grooming behaviors of Mecp2-knockdown (B) or Tsc1-knockdown (C) mice after treatment with D-cycloserine (DCS), fenobam, SCH23390, or ecopipam. (D~F) Experimental design of the social novelty preference test (D). Social novelty preference test of Mecp2-knockdown (E) or Tsc1-knockdown (F) mice after treatment with D-cycloserine (DCS), fenobam, SCH23390, or ecopipam. (G~I) Experimental design of the novel object preference test (G). Novel object preference test of Mecp2-knockdown (H) or Tsc1-knockdown (I) mice after treatment with D-cycloserine (DCS), fenobam, SCH23390, or ecopipam. Mecp2-siRNA, n=6–8 animals; Tsc1-siRNA, n=6–8 animals. Data are presented as mean±SEM. ^* and ^** denote the differences between the indicated groups at p<0.05 and p<0.01, respectively (One-way ANOVA, two-way ANOVA, and Holm-Sidak post hoc test).